Clinical Trials Browser

Phase NA × Myelodysplastic Syndromes × Bortezomib × Clear all

NCT00789256 2018-10-24

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

Phase NA Completed

26 enrolled 9 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute